TREM-话题@MedSci

#TREM#

40篇内容 | 1448人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1796381, encodeId=74201e96381d2, content=<a href='/topic/show?id=9a1b1e7916c' target=_blank style='color:#2F92EE;'>#TREM#</a>, objectTitle=durvalumab与tremelimumab的组合未能在NSCLC研究中击败化疗, objectType=article, longId=178104, objectId=13451e81046d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=13451e81046d, replyNumber=0, likeNumber=78, createdTime=2019-10-02, rootId=0, userName=ms3994565386320060, userId=a6a52500039, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=13451e81046d, moduleTitle=durvalumab与tremelimumab的组合未能在NSCLC研究中击败化疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=13451e81046d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796379, encodeId=c8551e96379db, content=<a href='/topic/show?id=9a1b1e7916c' target=_blank style='color:#2F92EE;'>#TREM#</a>, objectTitle=Lancet发表III期ECLIPSE研究，证明IL-23单抗TREMFYA比IL-17单抗COSENTYX治疗中度至重度银屑病具有更好的长期疗效, objectType=article, longId=177388, objectId=8ab51e73889d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ab51e73889d, replyNumber=0, likeNumber=64, createdTime=2020-05-07, rootId=0, userName=ms3994565386320060, userId=a6a52500039, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ab51e73889d, moduleTitle=Lancet发表III期ECLIPSE研究，证明IL-23单抗TREMFYA比IL-17单抗COSENTYX治疗中度至重度银屑病具有更好的长期疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ab51e73889d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796380, encodeId=7e141e963808d, content=<a href='/topic/show?id=9a1b1e7916c' target=_blank style='color:#2F92EE;'>#TREM#</a>, objectTitle=Sci transl med：MS4A基因调控TREM2的表达，影响AD发病风险, objectType=article, longId=177734, objectId=ec801e7734bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec801e7734bc, replyNumber=0, likeNumber=72, createdTime=2020-06-26, rootId=0, userName=ms3994565386320060, userId=a6a52500039, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec801e7734bc, moduleTitle=Sci transl med：MS4A基因调控TREM2的表达，影响AD发病风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec801e7734bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796383, encodeId=fb001e96383f1, content=<a href='/topic/show?id=9a1b1e7916c' target=_blank style='color:#2F92EE;'>#TREM#</a>, objectTitle=强生向欧洲药品管理局提交申请，寻求扩大其IL-23单抗Tremfya用于治疗银屑病关节炎, objectType=article, longId=181828, objectId=a684181828c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a684181828c3, replyNumber=0, likeNumber=83, createdTime=2020-09-04, rootId=0, userName=ms3994565386320060, userId=a6a52500039, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a684181828c3, moduleTitle=强生向欧洲药品管理局提交申请，寻求扩大其IL-23单抗Tremfya用于治疗银屑病关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a684181828c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796377, encodeId=47a01e963770b, content=<a href='/topic/show?id=9a1b1e7916c' target=_blank style='color:#2F92EE;'>#TREM#</a>, objectTitle=GUT：非实质性TREM-2可保护肝脏免受免疫介导的肝细胞损伤, objectType=article, longId=155015, objectId=4382155015e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4382155015e1, replyNumber=0, likeNumber=89, createdTime=2019-06-16, rootId=0, userName=ms3994565386320060, userId=a6a52500039, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4382155015e1, moduleTitle=GUT：非实质性TREM-2可保护肝脏免受免疫介导的肝细胞损伤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4382155015e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796382, encodeId=9d591e9638226, content=<a href='/topic/show?id=9a1b1e7916c' target=_blank style='color:#2F92EE;'>#TREM#</a>, objectTitle=头对头牛皮癣研究中，礼来的IL-17A单抗Taltz与强生的IL-23单抗Tremfya相比可提高皮肤清除率, objectType=article, longId=180571, objectId=711e1805e121, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=711e1805e121, replyNumber=0, likeNumber=72, createdTime=2019-11-29, rootId=0, userName=ms3994565386320060, userId=a6a52500039, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=711e1805e121, moduleTitle=头对头牛皮癣研究中，礼来的IL-17A单抗Taltz与强生的IL-23单抗Tremfya相比可提高皮肤清除率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=711e1805e121)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796374, encodeId=993c1e96374e5, content=<a href='/topic/show?id=9a1b1e7916c' target=_blank style='color:#2F92EE;'>#TREM#</a>, objectTitle=JAMA ONCOL：PD-L低表达的复发或转移头颈部鳞状细胞癌患者接受Durvalumab联合Tremelimumab治疗的安全性和有效性, objectType=article, longId=153283, objectId=aa13153283e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa13153283e8, replyNumber=0, likeNumber=73, createdTime=2019-02-07, rootId=0, userName=ms3994565386320060, userId=a6a52500039, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa13153283e8, moduleTitle=JAMA ONCOL：PD-L低表达的复发或转移头颈部鳞状细胞癌患者接受Durvalumab联合Tremelimumab治疗的安全性和有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa13153283e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796372, encodeId=07a11e9637219, content=<a href='/topic/show?id=9a1b1e7916c' target=_blank style='color:#2F92EE;'>#TREM#</a>, objectTitle=Janssen启动了Crohn''s药物Tremfya的PhII / III期计划, objectType=article, longId=144189, objectId=f0e314418910, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0e314418910, replyNumber=0, likeNumber=60, createdTime=2019-01-11, rootId=0, userName=ms3994565386320060, userId=a6a52500039, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0e314418910, moduleTitle=Janssen启动了Crohn''s药物Tremfya的PhII / III期计划, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0e314418910)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796371, encodeId=f7d71e96371e0, content=<a href='/topic/show?id=9a1b1e7916c' target=_blank style='color:#2F92EE;'>#TREM#</a>, objectTitle=J Clin Periodontol: 牙龈卟啉单胞菌LPs和Lr 12肽对单核细胞Trem-1表达的影响, objectType=article, longId=142097, objectId=0bf514209e34, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0bf514209e34, replyNumber=0, likeNumber=55, createdTime=2018-07-05, rootId=0, userName=ms3994565386320060, userId=a6a52500039, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0bf514209e34, moduleTitle=J Clin Periodontol: 牙龈卟啉单胞菌LPs和Lr 12肽对单核细胞Trem-1表达的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0bf514209e34)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796378, encodeId=d5e21e963783c, content=<a href='/topic/show?id=9a1b1e7916c' target=_blank style='color:#2F92EE;'>#TREM#</a>, objectTitle=美国FDA批准新型TREMFYA（guselkumab）制剂治疗成人中度至重度斑块型银屑病, objectType=article, longId=161432, objectId=c21f16143225, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c21f16143225, replyNumber=0, likeNumber=73, createdTime=2019-05-09, rootId=0, userName=ms3994565386320060, userId=a6a52500039, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c21f16143225, moduleTitle=美国FDA批准新型TREMFYA（guselkumab）制剂治疗成人中度至重度斑块型银屑病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c21f16143225)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796373, encodeId=01451e96373f3, content=<a href='/topic/show?id=9a1b1e7916c' target=_blank style='color:#2F92EE;'>#TREM#</a>, objectTitle=Lilly将启动IXORA-R头对头试验：比较IL-17A单抗Taltz和IL-23单抗Tremfya治疗中度至重度斑块型银屑病患者的疗效, objectType=article, longId=148645, objectId=6dae148645a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6dae148645a9, replyNumber=0, likeNumber=66, createdTime=2019-07-03, rootId=0, userName=ms3994565386320060, userId=a6a52500039, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6dae148645a9, moduleTitle=Lilly将启动IXORA-R头对头试验：比较IL-17A单抗Taltz和IL-23单抗Tremfya治疗中度至重度斑块型银屑病患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6dae148645a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796376, encodeId=5e401e96376a7, content=<a href='/topic/show?id=9a1b1e7916c' target=_blank style='color:#2F92EE;'>#TREM#</a>, objectTitle=Ann Neurol：血浆可溶性TREM2作为痴呆症的生物标志物, objectType=article, longId=154674, objectId=49811546e4e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=49811546e4e7, replyNumber=0, likeNumber=145, createdTime=2019-06-27, rootId=0, userName=ms3994565386320060, userId=a6a52500039, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=49811546e4e7, moduleTitle=Ann Neurol：血浆可溶性TREM2作为痴呆症的生物标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=49811546e4e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796375, encodeId=f7c61e9637541, content=<a href='/topic/show?id=9a1b1e7916c' target=_blank style='color:#2F92EE;'>#TREM#</a>, objectTitle=MYSTIC研究：durvalumab与tremelimumab联用无法显著提高肺癌患者的生存率, objectType=article, longId=153840, objectId=5663153840a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5663153840a9, replyNumber=0, likeNumber=95, createdTime=2019-01-28, rootId=0, userName=ms3994565386320060, userId=a6a52500039, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5663153840a9, moduleTitle=MYSTIC研究：durvalumab与tremelimumab联用无法显著提高肺癌患者的生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5663153840a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796369, encodeId=00b31e9636965, content=<a href='/topic/show?id=9a1b1e7916c' target=_blank style='color:#2F92EE;'>#TREM#</a>, objectTitle=NHS支持Janssen的Tremfya的使用, objectType=article, longId=137955, objectId=1cd213e9559f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1cd213e9559f, replyNumber=0, likeNumber=63, createdTime=2019-02-14, rootId=0, userName=ms3994565386320060, userId=a6a52500039, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1cd213e9559f, moduleTitle=NHS支持Janssen的Tremfya的使用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1cd213e9559f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796367, encodeId=00941e96367ce, content=<a href='/topic/show?id=9a1b1e7916c' target=_blank style='color:#2F92EE;'>#TREM#</a>, objectTitle=杨森银屑病新药Tremfya获批, objectType=article, longId=106037, objectId=898310603e6b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=898310603e6b, replyNumber=0, likeNumber=74, createdTime=2017-11-02, rootId=0, userName=ms3994565386320060, userId=a6a52500039, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=898310603e6b, moduleTitle=杨森银屑病新药Tremfya获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=898310603e6b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796370, encodeId=352a1e9637024, content=<a href='/topic/show?id=9a1b1e7916c' target=_blank style='color:#2F92EE;'>#TREM#</a>, objectTitle=Lancet respir med：Tremelimumab（抗CTLA4单克隆抗体）联合durvalumab（抗PD-L1单克隆抗体）用于间皮瘤的疗效和安全性, objectType=article, longId=138186, objectId=481213818605, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=481213818605, replyNumber=0, likeNumber=73, createdTime=2019-01-31, rootId=0, userName=ms3994565386320060, userId=a6a52500039, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=481213818605, moduleTitle=Lancet respir med：Tremelimumab（抗CTLA4单克隆抗体）联合durvalumab（抗PD-L1单克隆抗体）用于间皮瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=481213818605)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796366, encodeId=397f1e9636680, content=<a href='/topic/show?id=9a1b1e7916c' target=_blank style='color:#2F92EE;'>#TREM#</a>, objectTitle=银屑病患者福音：FDA批准强生公司新药tremfya, objectType=article, longId=105620, objectId=b1e3105620cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b1e3105620cc, replyNumber=0, likeNumber=62, createdTime=2018-06-26, rootId=0, userName=ms3994565386320060, userId=a6a52500039, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b1e3105620cc, moduleTitle=银屑病患者福音：FDA批准强生公司新药tremfya, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b1e3105620cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796368, encodeId=315f1e963684d, content=<a href='/topic/show?id=9a1b1e7916c' target=_blank style='color:#2F92EE;'>#TREM#</a>, objectTitle=英国推出Janssen的新型银屑病生物制剂Tremfya, objectType=article, longId=121472, objectId=ec8c1214e24c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec8c1214e24c, replyNumber=0, likeNumber=74, createdTime=2018-09-08, rootId=0, userName=ms3994565386320060, userId=a6a52500039, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec8c1214e24c, moduleTitle=英国推出Janssen的新型银屑病生物制剂Tremfya, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec8c1214e24c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796365, encodeId=a4e81e963656f, content=<a href='/topic/show?id=9a1b1e7916c' target=_blank style='color:#2F92EE;'>#TREM#</a>, objectTitle=J Hepatol：Tremelimumab治疗晚期肝癌的可行性研究, objectType=article, longId=82155, objectId=192282155c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=192282155c5, replyNumber=0, likeNumber=61, createdTime=2016-11-28, rootId=0, userName=ms3994565386320060, userId=a6a52500039, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=192282155c5, moduleTitle=J Hepatol：Tremelimumab治疗晚期肝癌的可行性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=192282155c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796364, encodeId=c1f71e9636487, content=<a href='/topic/show?id=9a1b1e7916c' target=_blank style='color:#2F92EE;'>#TREM#</a>, objectTitle=Cancer Res：靶向炎症促发因子TREM-1预防治疗癌症, objectType=article, longId=9300, objectId=bd649300cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bd649300cb, replyNumber=0, likeNumber=97, createdTime=2013-01-26, rootId=0, userName=ms3994565386320060, userId=a6a52500039, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bd649300cb, moduleTitle=Cancer Res：靶向炎症促发因子TREM-1预防治疗癌症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bd649300cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

TREM

2020-05-29

ms3994565386320060 (审核中...)

前往app查看评论内容

#TREM#

durvalumab与tremelimumab的组合未能在NSCLC研究中击败化疗

2019-10-02

ms3994565386320060 (审核中...)

前往app查看评论内容

#TREM#

Lancet发表III期ECLIPSE研究，证明IL-23单抗TREMFYA比IL-17单抗COSENTYX治疗中度至重度银屑病具有更好的长期疗效

2020-05-07

ms3994565386320060 (审核中...)

前往app查看评论内容

#TREM#

Sci transl med：MS4A基因调控TREM2的表达，影响AD发病风险

2020-06-26

ms3994565386320060 (审核中...)

前往app查看评论内容

#TREM#

强生向欧洲药品管理局提交申请，寻求扩大其IL-23单抗Tremfya用于治疗银屑病关节炎

2020-09-04

ms3994565386320060 (审核中...)

前往app查看评论内容

#TREM#

GUT：非实质性TREM-2可保护肝脏免受免疫介导的肝细胞损伤

2019-06-16

ms3994565386320060 (审核中...)

前往app查看评论内容

#TREM#

头对头牛皮癣研究中，礼来的IL-17A单抗Taltz与强生的IL-23单抗Tremfya相比可提高皮肤清除率

2019-11-29

ms3994565386320060 (审核中...)

前往app查看评论内容

#TREM#

JAMA ONCOL：PD-L低表达的复发或转移头颈部鳞状细胞癌患者接受Durvalumab联合Tremelimumab治疗的安全性和有效性

2019-02-07

ms3994565386320060 (审核中...)

前往app查看评论内容

#TREM#

Janssen启动了Crohn''s药物Tremfya的PhII / III期计划

2019-01-11

ms3994565386320060 (审核中...)

前往app查看评论内容

#TREM#

J Clin Periodontol: 牙龈卟啉单胞菌LPs和Lr 12肽对单核细胞Trem-1表达的影响

2018-07-05

ms3994565386320060 (审核中...)

前往app查看评论内容

#TREM#

美国FDA批准新型TREMFYA（guselkumab）制剂治疗成人中度至重度斑块型银屑病

2019-05-09

ms3994565386320060 (审核中...)

前往app查看评论内容

#TREM#

Lilly将启动IXORA-R头对头试验：比较IL-17A单抗Taltz和IL-23单抗Tremfya治疗中度至重度斑块型银屑病患者的疗效

2019-07-03

ms3994565386320060 (审核中...)

前往app查看评论内容

#TREM#

Ann Neurol：血浆可溶性TREM2作为痴呆症的生物标志物

2019-06-27

ms3994565386320060 (审核中...)

前往app查看评论内容

#TREM#

MYSTIC研究：durvalumab与tremelimumab联用无法显著提高肺癌患者的生存率

2019-01-28

ms3994565386320060 (审核中...)

前往app查看评论内容

#TREM#

NHS支持Janssen的Tremfya的使用

2019-02-14

ms3994565386320060 (审核中...)

前往app查看评论内容

#TREM#

杨森银屑病新药Tremfya获批

2017-11-02

ms3994565386320060 (审核中...)

前往app查看评论内容

#TREM#

Lancet respir med：Tremelimumab（抗CTLA4单克隆抗体）联合durvalumab（抗PD-L1单克隆抗体）用于间皮瘤的疗效和安全性

2019-01-31

ms3994565386320060 (审核中...)

前往app查看评论内容

#TREM#

银屑病患者福音：FDA批准强生公司新药tremfya

2018-06-26

ms3994565386320060 (审核中...)

前往app查看评论内容

#TREM#

英国推出Janssen的新型银屑病生物制剂Tremfya

2018-09-08

ms3994565386320060 (审核中...)

前往app查看评论内容

#TREM#

J Hepatol：Tremelimumab治疗晚期肝癌的可行性研究

2016-11-28

ms3994565386320060 (审核中...)

前往app查看评论内容

#TREM#

Cancer Res：靶向炎症促发因子TREM-1预防治疗癌症

2013-01-26

科室
- - 订阅+
  - 更多科室
工具
服务